Strategic CRO Growth Neopharm Boston has expanded to offer a fully integrated suite of development through commercial launch services, signaling readiness for end-to-end collaboration with pharma clients seeking streamlined development pipelines.

Acquisition Momentum Recent acquisitions and partnerships, including MS Pharma Group and the Averica Discovery collaboration, indicate an active strategy to broaden capabilities and territorial footprint in small molecule analysis and purification.

High Throughput Advantage Strength in high throughput capabilities paired with a skilled team positions Neopharm Boston as a compelling partner for clients needing rapid analytical development, screening, and purification at multiple development stages.

Hub for Innovation Investments in equipment and advanced analytics since 2017, plus a breadth of tech stack and cloud-based tools, suggest a scalable platform that can support growing client demand for cutting-edge small molecule services.

Mid-Sized Opportunity With a revenue range of 1 to 10 million and a lean employee base, Neopharm Boston appears well-suited to engage mid-market pharma companies seeking cost-effective CRO partnerships with personalized service.